Description
The 16A1 monoclonal antibody specifically recognizes human CD140a which is also known as human platelet derived growth factor receptor α (PDGFRα). CD140a (PDGFRα) is an ~170 kDa single pass type I transmembrane glycoprotein that is encoded by PDGFRA (platelet derived growth factor receptor alpha) which belongs to the receptor tyrosine kinase (RTK) class III family. This receptor is comprised of an N-terminal extracellular domain with five IgC2-like domains, and a transmembrane sequence followed by a cytoplasmic region with a split tyrosine kinase domain. CD140a (PDGFRα) is expressed on a variety of cell types including platelets, monocytes, fibroblasts, endothelial cells, smooth muscle cells, glial cells, chondrocytes as well as numerous tumor cell types. PDGFRα dimerizes and autophosphorylates when binding to homodimeric or heterodimeric platelet-derived growth factors (PDGF) comprised of disulfide-bonded A, B, or C (but not D) isoforms, ie, PDGF-AA, PDGF-AB, PDGF-BB, and PDGF-CC. PDGFRα can also heterodimerize with platelet derived growth factor receptor β (PDGFRβ, also known as CD140b) and autophosphorylate upon binding to PDGF-AB, PDGF-BB, and possibly PDGF-CC and PDGF-DD. Homodimerized CD140b (PDGFRβ) is activated by PDGF-BB and PDGF-DD. PDGF ligands stimulate the growth, proliferation, migration, and survival of PDGF Receptor-positive normal cells as well as tumor cells. CD140a (PDGFRα) plays key roles in multiple processes including embryonic development, wound healing, and the regulation of platelet activation.
BD™ CompBeads can be used as surrogates to assess fluorescence spillover (Compensation). When fluorochrome conjugated antibodies are bound to CompBeads, they have spectral properties very similar to cells. However, for some fluorochromes there can be small differences in spectral emissions compared to cells, resulting in spillover values that differ when compared to biological controls. It is strongly recommended that when using a reagent for the first time, users compare the spillover on cells and CompBead to ensure that BD Comp beads are appropriate for your specific cellular application. For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes are used in the same experiment. Fluorescent dye interactions may cause staining artifacts which may affect data interpretation. The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions. More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794/566349) or the BD Horizon Brilliant Stain Buffer Plus (Cat. No. 566385).
Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated to the dye under optimum conditions that minimize unconjugated dye and antibody.
1. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
2. Researchers should determine the optimal concentration of this reagent for their individual applications.
3. An isotype control should be used at the same concentration as the antibody of interest.
4. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
5. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at www.bdbiosciences.com/colors.
6. Please refer to www.bdbiosciences.com/us/s/resources for technical protocols.
7. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
8. Please refer to http://regdocs.bd.com to access safety data sheets (SDS).
9. BD Horizon Brilliant Ultraviolet 395 is covered by one or more of the following US patents: 8,158,444; 8,575,303; 8,354,239.
